Product Description
Mechanisms of Action: PNP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Known Adverse Events: None
Company: BioCryst
Company Location: DURHAM NC 27703
Company CEO: Jon P. Stonehouse
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: T-Cell Cutaneous Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Arthritis, Rheumatoid|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|B-Cell Leukemia|Osteoarthritis|Acute Lymphoid Leukemia|Type 2 Diabetes|Burkitt Lymphoma|Lymphoma, Non-Hodgkin|T-Cell Peripheral Lymphoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma|T-Cell Lymphoma|Lymphoid Leukemia|Leukemia
Phase 1: Chronic Myeloid Leukemia|Hairy Cell Leukemia|Granular Cell Tumor|Prolymphocytic Leukemia|Liver Cirrhosis|Lymphocytic Chronic B-Cell Leukemia|Glioblastoma|Esophageal Cancer|Acute Monocytic Leukemia|Large Cell Carcinoma|Mycosis Fungoides|NUT Carcinoma|Prolymphocytic T-Cell Leukemia|Follicular Adenocarcinoma|Follicular Lymphoma|Central Nervous System Cancer|Brain Stem Cancer|Pancreatic Cancer|Prolymphocytic B-Cell Leukemia|Leukemia, Neutrophilic, Chronic|Acute Eosinophilic Leukemia|Ovarian Cancer|Acute Myelomonocytic Leukemia|Colorectal Cancer|Gastrointestinal Cancer|Polycythemia Vera|Sarcoma, Myeloid|Giant Cell Carcinoma|Chronic Myelomonocytic Leukemia|Lymphoma, Non-Hodgkin|Multiple Myeloma|Primary Cutaneous Anaplastic Large Cell Lymphoma|Sezary Syndrome|Chronic Lymphoid Leukemia|Primary Central Nervous System Lymphoma|Melanoma|Abnormalities, Multiple|Acute Lymphoid Leukemia|Thrombocythemia, Essential|Liver Cancer|Astrocytoma|Large Granular Lymphocytic Leukemia|Acute Myeloid Leukemia|Splenic Cancer|Myelofibrosis|Diffuse Large B-Cell Lymphoma|Myelodysplastic Syndrome|T-Cell Cutaneous Lymphoma|Bile Duct Cancer|Intraocular Lymphoma|Ependymoma|Gliosarcoma|B-Cell Marginal Zone Lymphoma|Burkitt Lymphoma|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Oncology Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-121985 | P2 |
Completed |
T-Cell Peripheral Lymphoma |
2016-12-31 |
|
| FDS-J02 | P2 |
Completed |
T-Cell Peripheral Lymphoma |
2016-03-01 |
|
| BCX1777-J01 | P1 |
Completed |
Oncology Unspecified |
2013-08-01 |
|
| forodesine in CTCL | P2 |
Completed |
T-Cell Cutaneous Lymphoma |
2011-12-07 |